Active Ingredient History
Farletuzumab (MORAb-003) is a humanized monoclonal antibody of IgG1/κ which is being investigated for the treatment of ovarian cancer. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma of Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Neoplasms (Phase 1)
Ovarian Neoplasms (Phase 3)
Peritoneal Neoplasms (Phase 2)
Pituitary Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue